224 related articles for article (PubMed ID: 28661478)
1. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.
Kurt IC; Sur I; Kaya E; Cingoz A; Kazancioglu S; Kahya Z; Toparlak OD; Senbabaoglu F; Kaya Z; Ozyerli E; Karahüseyinoglu S; Lack NA; Gümüs ZH; Onder TT; Bagci-Onder T
Cell Death Dis; 2017 Jun; 8(6):e2897. PubMed ID: 28661478
[TBL] [Abstract][Full Text] [Related]
2. The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Alkahtani S; Alarifi S; Tsichlis PN; Kampranis SC; Stournaras C
Cell Physiol Biochem; 2018; 47(1):368-377. PubMed ID: 29772566
[TBL] [Abstract][Full Text] [Related]
3. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
5. The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Tsichlis PN; Kampranis SC; Stournaras C
Biochim Biophys Acta Mol Cell Res; 2018 Apr; 1865(4):587-597. PubMed ID: 29408056
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
[TBL] [Abstract][Full Text] [Related]
7. KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin-1-mediated chromatin silencing.
Kang JY; Kim JY; Kim KB; Park JW; Cho H; Hahm JY; Chae YC; Kim D; Kook H; Rhee S; Ha NC; Seo SB
FASEB J; 2018 Oct; 32(10):5737-5750. PubMed ID: 29763382
[TBL] [Abstract][Full Text] [Related]
8. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
[TBL] [Abstract][Full Text] [Related]
9. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
[TBL] [Abstract][Full Text] [Related]
10. BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas.
Burton TR; Henson ES; Azad MB; Brown M; Eisenstat DD; Gibson SB
Cell Death Dis; 2013 Apr; 4(4):e587. PubMed ID: 23579274
[TBL] [Abstract][Full Text] [Related]
11. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Staberg M; Rasmussen RD; Michaelsen SR; Pedersen H; Jensen KE; Villingshøj M; Skjoth-Rasmussen J; Brennum J; Vitting-Seerup K; Poulsen HS; Hamerlik P
Mol Oncol; 2018 Mar; 12(3):406-420. PubMed ID: 29360266
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4.
Chavdoula E; Anastas V; La Ferlita A; Aldana J; Carota G; Spampinato M; Soysal B; Cosentini I; Parashar S; Sircar A; Nigita G; Sehgal L; Freitas MA; Tsichlis PN
Metabolism; 2024 Jan; 150():155719. PubMed ID: 37935302
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A; Siegelin MD; Steinmüller A; von Deimling A; Lass U; Korn B; Mueller W
Clin Cancer Res; 2009 Sep; 15(17):5457-65. PubMed ID: 19706813
[TBL] [Abstract][Full Text] [Related]
15. Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes.
He J; Shen L; Wan M; Taranova O; Wu H; Zhang Y
Nat Cell Biol; 2013 Apr; 15(4):373-84. PubMed ID: 23502314
[TBL] [Abstract][Full Text] [Related]
16. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
17. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
Wanna-Udom S; Terashima M; Suphakhong K; Ishimura A; Takino T; Suzuki T
J Biol Chem; 2021; 296():100213. PubMed ID: 33779563
[TBL] [Abstract][Full Text] [Related]
18. Depletion of histone demethylase KDM2A inhibited cell proliferation of stem cells from apical papilla by de-repression of p15INK4B and p27Kip1.
Gao R; Dong R; Du J; Ma P; Wang S; Fan Z
Mol Cell Biochem; 2013 Jul; 379(1-2):115-22. PubMed ID: 23559091
[TBL] [Abstract][Full Text] [Related]
19. The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
Zacharopoulou N; Kallergi G; Alkahtani S; Tsapara A; Alarifi S; Schmid E; Sukkar B; Kampranis S; Lang F; Stournaras C
Cancer Biol Ther; 2020 Jun; 21(6):533-540. PubMed ID: 32175798
[TBL] [Abstract][Full Text] [Related]
20. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
Tzatsos A; Paskaleva P; Ferrari F; Deshpande V; Stoykova S; Contino G; Wong KK; Lan F; Trojer P; Park PJ; Bardeesy N
J Clin Invest; 2013 Feb; 123(2):727-39. PubMed ID: 23321669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
